Myelodysplastic Syndromes
The latest news, research, and perspectives in myelodysplastic syndromes (MDS). Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.
Eprenetapopt and azacitidine after allogeneic HSCT was well tolerated in patients with TP53-mutated AML and MDS.
Venetoclax and azacitidine in R/R MDS demonstrated a manageable safety profile with meaningful clinical benefits...
Further development of BI 836858 was discontinued after it failed to elicit a response in transfusion-dependent.
Azacitidine may be a treatment option for patients with SAID associated with MDS and CMML.
A prospective study failed to confirm the general predictive value of a biomarker-driven prediction model.
HLA-matched sibling donors are the preferred transplant choice for MDS.
A study showed "unexpected" results related to race and MDS survival...
Nearly a third (30%) of patients with higher-risk MDS have an overexpression of the RARA gene...
The classification process is mainly based on two processes, class discovery and class prediction...
Phillip Scheinberg, MD, PhD, discusses myelodysplastic syndromes at the 2022 SOHO Annual Meeting...
ASTX727 is an oral fixed-dose combination of HMA decitabine and cytidine deaminase inhibitor cedazuridine...
Blood Cancers Today interviewed Dr. Diez-Campelo after her presentation titled, “Treatment of Lower Risk MDS.”
Researchers retrospectively assessed 135 untreated patients with MDS who later developed HMA-F...
Researchers investigated its use in patients undergoing mismatched donor HSCT with post-transplant cyclophosphamide...
Lionel Adès, MD, PhD, spoke with Blood Cancers Today about the session he presented at the 2022 SOHO Annual Meeting...
The outcomes of AML transformation after HMA-failure MDS remain extremely poor...
Azacitidine is the current standard of care, and magrolimab is a monoclonal antibody blocking CD47 expression...
During the 2022 SOHO Annual Meeting, Jacqueline S. Garcia, MD, discussed immunotherapies for myelodysplastic syndromes...
There was no significant difference between patients treated with azacitidine on a five-day or a five-plus-two-day schedule..
Dr. Garcia-Manero talks about what a “total approach” to MDS means to him...
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Assistant Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Advertisement
670 Madison Ave.
Manalapan, NJ 07726
© 2022 Mashup Media, LLC. All rights reserved.